Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...
James Dentzer, President and CEO, stated that "we continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results